A stimulating advance in erythropoiesis for patients with myelodysplastic syndromes.

Competing Interests: YFM has received honoraria or consulting fees from BMS, Kura Oncology, BluePrint Medicines, Geron, OncLive and MD Education, VJHemOnc, and Medscape Live; has participated in advisory boards and received honoraria from Sierra Oncology, Stemline Therapeutics, Blueprint Medicines, Morphosys, Taiho Oncology, SOBI, Rigel Pharmaceuticals, Geron, Cogent Biosciences, and Novartis; and has received travel reimbursement from Blueprint Medicines, MD Education, and Morphosys. AED has participated in advisory boards or had a consultancy with and received honoraria from Celgene/BMS, Agios, Novartis, Appellis, and Gilead; and has served on clinical trial committees or data safety and monitoring boards for Novartis, AbbVie, Kura, Geron, Servier, Keros, Shuattuck Labs, and Celgene/BMS.